Objective: To better understand risk factors for pneumonia hospitalizations in people with impaired lung function. Methods: We analyzed longitudinal data from participants in the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS). We limited our analysis to 20,375 participants aged 45 and older at baseline. We stratified the sample based on prebronchodilator baseline lung function data, according to modified GOLD criteria, including a ''restrictive'' category (FEV 1 /FVC > 70% and FVC < 80%). We defined ''pneumonia'' as a hospitalization with a pneumonia discharge diagnosis (ICD-9 codes 480e486) within 36 months. We used Cox proportional hazard models to determine pneumonia risk associated with COPD stage, adjusting for age, sex, race, smoking status and comorbid disease (diabetes mellitus or cardiovascular disease at the baseline examination). Results: Pneumonia hospitalization risk was associated with older age, male gender, comorbid conditions, smoking status, and level of lung function impairment. Overall, people with normal lung function had the lowest pneumonia hospitalization rate (1.5 per 1000 person-years) and those with GOLD stage 3 or 4 COPD had the highest rate (22.7 per 1000 person-years). After adjusting for other potential confounding factors, GOLD stages 3 or 4 and 2 COPD were associated with an increased risk of pneumonia (hazard ratio [HR] 5.65, 95% confidence interval [CI] 3.29, 9.67 and 2.25 (1.35, 3.75), respectively) relative to normal lung function. Conclusion: COPD severity (GOLD stage) is an important and independent predictor of pneumonia hospitalizations in this cohort. ª
Introduction
Pneumonia remains an important cause of morbidity and mortality in the United States, accounting for more than 5 million cases, 1.3 million hospitalizations, and 60,000 deaths annually.
1e4 Pneumonia is particularly problematic in the elderly and among people with underlying diseases, such as chronic obstructive pulmonary disease (COPD), diabetes mellitus, and cardiovascular disease. 4 In a review of 2.3 million US pneumonia hospitalizations among people 65 years and older during the years 2000e2002, Fry et al found that 57% had prevalent cardiac disease, 47% had COPD, and 20% had diabetes mellitus. 4 Overall in-hospital mortality in this study, among patients with pneumonia, was 13.8%. 4 In a separate study, Holguin et al found that over the period of 1996e2001, the in-hospital mortality among patients with COPD and pneumonia was double that of patients with pneumonia only (38% vs. 18%) and COPD was associated with a three-fold increase in the risk of comorbid pneumonia (14% vs. 4%). 5 We used a modification of the Global Initiative on Obstructive Lung Disease (GOLD) classification criteria, 6, 7 incorporating a classification for restrictive disease, 8 to examine the association between impaired lung function at baseline and the occurrence of a hospitalization related to pneumonia in a cohort of US adults aged 45 and older comprised of participants in the Atherosclerosis Risk in Communities Study (ARIC) 9 and the Cardiovascular Health Study (CHS). 10 
Methods
For this analysis we combined data from the CHS and ARIC cohorts, both of which were population-based NIH cohorts initiated in the late 1980s to study risk factors for the development and progression of heart disease and stroke. These cohorts included subjects of different ages (65 years and older for CHS and 45e64 years old for ARIC) and had comprehensive evaluations including lung function and longitudinal follow-up. Combining these two cohorts into one larger study population provides data over a wider age range better reflecting the US adult population.
Study population: CHS
The original CHS cohort of 5201 men and women was selected using Medicare eligibility lists provided by the US Health Care Financing Administration for four communities: Forsyth County, North Carolina; Pittsburgh, Pennsylvania; Sacramento County, California; and Washington County, Maryland during the period from May 1989 to May 1990. 10 CHS participants underwent pulmonary function testing during a baseline clinical examination and provided information on the history of respiratory symptoms and diagnoses, BMI, smoking history, and medical history. Study protocols were approved for the protection of human subjects. Details of the CHS are published elsewhere. 10 Our analysis was limited to CHS participants who provided baseline information on respiratory symptoms, underwent pulmonary function testing at the baseline examination, and for whom follow-up data were available.
Study population: ARIC
The ARIC cohort of 15,792 men and women was initiated in 1986 as a longitudinal, population-based study of the etiology and clinical sequelae of atherosclerosis. Study protocols were approved for the protection of human subjects. Details of the ARIC study are published elsewhere. 9 Our analysis was limited to ARIC participants aged 45e64 years, who provided baseline information on respiratory symptoms, who underwent pulmonary function testing at the baseline examination, and for whom followup data were available.
Pulmonary function data
Spirometry was conducted using a volume displacement, water-sealed spirometer. At least three acceptable spirograms were obtained from a minimum of five forced expirations. The best single spirogram was identified by a computer and confirmed by a technician. Quality assurance was provided by the CHS Pulmonary Function Center for CHS and the ARIC investigators for ARIC, and the procedures followed contemporary American Thoracic Society guidelines. 11 Several measures of lung function were used in this analysis: the forced expiratory volume in 1 s (FEV 1 ), the forced vital capacity (FVC), and the FEV 1 /FVC ratio. We used prediction equations derived from the Third National Health and Nutrition Examination Survey to define the predicted values of FEV 1 and FVC. 12 
Variable definition
Age, sex, race and the highest education level obtained were self-reported. Age was stratified into 4 year categories, race was classified as white or black, and education level was classified as <12 years, 12 years, or more than 12 years.
Respondents with positive responses to ''Have you ever smoked cigarettes?'' and ''Do you now smoke cigarettes?'' were classified as ''ever smokers'' and ''current smokers,'' respectively. Pack-years of cigarettes smoked were calculated for the current and former smokers. BMI was calculated as weight divided by the height squared (kg/m 2 ). 13 We defined a participant as having a respiratory symptom (used to classify the GOLD 0 lung function status) if they responded positively to any of the following questions: Do you usually have a cough? Do you usually bring up phlegm from your chest? Does your chest ever sound wheezy or whistling apart from colds? Do you have to walk slower than people of your age on the level because of breathlessness? Are you too breathless to leave the house or breathless on dressing or undressing?
Using a modification of the criteria developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 6 we classified subjects according to their GOLD stages of chronic obstructive pulmonary disease (COPD): GOLD stage 3 or 4 (FEV 1 /FVC < 0.70 and FEV 1 < 50% predicted), GOLD stage 2 (FEV 1 /FVC < 0.70 and FEV 1 50 to <80% predicted), GOLD stage 1 (FEV 1 /FVC < 0.70 and FEV 1 80%), restricted (FEV 1 /FVC 0.70 and FVC < 80% predicted), GOLD stage 0 (presence of respiratory symptoms in the absence of any lung function abnormality), and no lung disease. GOLD stage 0 does not appear in the most recent guideline revisions but we have included it in our analyses as we have previously demonstrated adverse outcomes among people in this category. 8 Bronchodilator response was not evaluated in this survey; so the classification is based on the ''prebronchodilator'' level. Subjects were classified as having diabetes if they either reported a diagnosis of diabetes at baseline or had impaired fasting or post glucose load glucose levels (>140) at the examination. Subjects reporting a diagnosis of a previous myocardial infarction, stroke, heart failure, angina, or transient ischemic attacks were classified as having prevalent cardiovascular disease at the baseline examination.
Pneumonia definition
Hospitalization data were searched and events were defined as any hospitalizations that occurred during 3 years of follow-up after the baseline evaluation that included a pneumonia (ICD-9 codes 480e486) discharge code.
Analysis
All analyses were conducted with SAS version 9.1 (SAS Institute, Cary, NC), SUDAAN version 9.0 (RTI, Research Triangle Park, NC) and SPSS version 10 (SPSS Inc, Chicago, IL).
Our primary outcome of interest in the survival models was pneumonia hospitalization that occurred during the first 3 years of follow-up, and the main predictor of interest in our analysis was COPD severity defined by the modified GOLD stage of lung function. We calculated the total number of pneumonia hospitalizations per 1000 personyears of follow-up for our key covariates. Cox proportional hazard regression models were developed using the SUDAAN procedure SURVIVAL to account for differential follow-up in cohort participants. Time of follow-up was used as the underlying time metric. Censoring occurred at the date of the first pneumonia hospitalization, date of death reported on the death certificate or date the participant was last known to be alive on. Plots of the loglog survival curves for each covariate were produced to evaluate the proportional hazards assumptions. Age, sex, race, smoking status, education level, body mass index, diabetes status, and cardiovascular disease status were included in the adjusted models.
Results
We were able to include 15,414 of 15,792 (97.6%) participants in the ARIC cohort and 4961 of 5201 (95.4%) participants in the CHS cohort in this analysis. The demographic characteristics of the 20,375 subjects included in the analysis are displayed in Table 1 . Overall, 534 (2.6%) subjects met the criteria for GOLD stage 3 or 4 at baseline, and an additional 2081 (10.2%) met the criteria for GOLD stage 2.
In the entire cohort, 214 of 20,375 subjects (1.1%) had one or more hospitalizations with a pneumonia discharge diagnosis during the 3-year follow-up period. Of these 214, 21 (9.8%) had one or more additional pneumonia hospitalizations during that same 3-year period. Of the 214 subjects, 32 (15.0%) died during their final pneumoniarelated hospitalization.
The rate of pneumonia hospitalizations, per 1000 person-years, varied by age, race, sex, smoking status, GOLD category, education level, and the presence of comorbid cardiovascular disease or diabetes mellitus (Table 1) . These rates, per 1000 person-years, ranged from 0.8 among people aged 50e54 years at baseline to 19.5 among people aged 80 and older (Table 1) . Similarly, the rates varied dramatically by lung function impairment from 1.5 per 1000 person-years among people with normal lung function to 22.7 per 1000 person-years among people with GOLD stage 3 or 4 COPD (Table 1) .
In both the unadjusted and fully adjusted Cox proportional hazard models (Table 2) , age greater than 60 years, male sex, current smoking status, lower education levels, diabetes mellitus, cardiovascular disease, a BMI of <20, and several categories of lung function impairment predicted pneumonia hospitalization. Of note, participants with GOLD stage 3 or 4 COPD at baseline had a much greater risk of pneumonia during follow-up (hazard ratio [HR] 5.65, 95% confidence interval [CI] 3.29, 9.67) compared to those with normal lung function. Similarly, current smokers had an increased risk of pneumonia hospitalizations (HR 2.21, 95% CI 1.52, 3.22). The association between smoking, GOLD category, and pneumonia hospitalizations is shown in Fig. 1 and demonstrates that the highest pneumonia hospitalization rates occurred in current and former smokers with GOLD stage 3 or 4 COPD (Fig. 1) .
Discussion
In this analysis of data from over 20,000 US adults, we found that age greater than 60 years, male sex, current smoking status, and the presence of GOLD stage 2 or more severe COPD were independent predictors of pneumonia hospitalizations during 3 years of follow-up. In addition, the presence of other chronic diseases including diabetes mellitus and cardiovascular disease also conferred an increased risk of subsequent pneumonia. Finally, we found that the in-hospital mortality among study participants with a pneumonia hospitalization was 15.0%.
Pneumonia hospitalizations have been trending upwards in the US in recent years. 4 The primary reason for this appears to be aging of the population and better treatment of chronic diseases such as COPD and cardiovascular disease, resulting in a larger pool of at risk adults. 4 While Fry et al found an increasing trend in pneumonia hospitalizations from 1988 to 2002, they also found a decrease in the in-hospital mortality from 20.3% in 1988e1990 to 13.8% in 2000e2002. 4 The in-hospital mortality rate in the combined ARIC and CHS cohorts was 15% for participants with a pneumonia hospitalization, although our population included adults as young as 45 at the initial evaluation and hospitalizations during our study would have occurred in the late 1980s and early 1990s.
The overall pneumonia hospitalization rate in our study population was 3.9 per 1000 person-years for ages 45þ years, which is lower than the 11.5 per 1000 person-years reported by Jackson et al 14 and the 10.1 per 1000 personyears reported by Marston et al. 15 Both of those previous studies, however, evaluated study samples of older adults aged 65 and older. The age-specific hospitalization rates (per 1000 person-years) reported by Jackson et al of 4.9 for 65e69-year-olds, 6.5 for 70e74-year-olds, and 10.8 for 75e 79-year-olds are very similar to what we reported. In an earlier analysis of the CHS data, the overall hospitalization rate for pneumonia was 11.1 per 1000 person-years. 16 We observed that older age was the strongest predictor of pneumonia risk in this population-based cohort, which is similar to what has been documented in other studies. 4,14e16 Our findings of an increased risk for the male sex, current smoking, diabetes mellitus, and COPD were also similar to what was reported by Jackson et al in their community-based study.
14 In an observational study of the universally insured elderly population of Quebec aged 65 and older, Ernst et al reported the rate of pneumonia hospitalizations to be 1.9 per 100 annually, 17 close to the 22.7 per 1000 annual rate of pneumonia hospitalizations we found in GOLD stage 3 and 4 COPD ( Table 1) .
This analysis of the ARIC and CHS cohort populations had certain limitations. We were only able to evaluate pneumonia hospitalizations according to the discharge diagnoses, which may comprise 20e40% of the total pneumonias, thereby missing the majority of pneumonia episodes mild enough to be treated in the clinic without a hospital admission.
2,14,18 Additionally, these pneumonias were not independently or bacteriologically validated leading to the potential for non-differential misclassification which would bias any association towards a null finding. In a prior analysis of pneumonia at one of the CHS sites, among 138 hospitalizations for which an ICD-9 coded for pneumonia was listed, this was confirmed clinically in 96% of cases and bacteriologically in 41% of cases. 16 In addition, we were not able to separate out pneumonias that originated in the community from those nosocomial infections contracted in a hospital or other health care settings. We were not able to assess the role of recent medication use, such as bronchodilators or corticosteroids, as a potential risk factor for pneumonia, because the participants' medication use was only assessed at the baseline survey and interval surveys and not at the time of hospitalization.
Conclusion
Pneumonia is a common cause of hospitalizations and mortality. Advanced age, cigarette smoking, male sex, and the presence of chronic diseases such as COPD, cardiovascular disease and diabetes mellitus were all associated with a significant increased risk of pneumonia hospitalizations in this large US population-based adult cohort.
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